Heska (HSKA) Now Covered by Analysts at Benchmark

Share on StockTwits

Stock analysts at Benchmark assumed coverage on shares of Heska (NASDAQ:HSKA) in a report issued on Thursday. The firm set a “buy” rating and a $120.00 price target on the medical research company’s stock. Benchmark’s price target would indicate a potential upside of 11.35% from the stock’s current price.

HSKA has been the topic of several other research reports. ValuEngine downgraded Heska from a “buy” rating to a “hold” rating in a report on Thursday, June 21st. BidaskClub upgraded Heska from a “hold” rating to a “buy” rating in a report on Saturday, April 21st. TheStreet upgraded Heska from a “c+” rating to a “b-” rating in a report on Thursday, May 31st. Zacks Investment Research upgraded Heska from a “strong sell” rating to a “hold” rating in a report on Wednesday. Finally, B. Riley boosted their price objective on Heska from $77.00 to $93.00 and gave the company a “neutral” rating in a report on Friday, May 18th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Heska has a consensus rating of “Buy” and an average price target of $111.42.

NASDAQ:HSKA opened at $107.77 on Thursday. Heska has a 52 week low of $56.59 and a 52 week high of $115.00. The firm has a market capitalization of $815.40 million, a price-to-earnings ratio of 52.06 and a beta of 0.75.

Heska (NASDAQ:HSKA) last posted its earnings results on Friday, May 4th. The medical research company reported $0.28 EPS for the quarter, missing the Zacks’ consensus estimate of $0.40 by ($0.12). The business had revenue of $32.77 million during the quarter, compared to analysts’ expectations of $31.65 million. Heska had a net margin of 5.57% and a return on equity of 13.30%. equities research analysts expect that Heska will post 1.68 EPS for the current fiscal year.

In related news, Director Bonnie J. Trowbridge sold 5,000 shares of the business’s stock in a transaction on Tuesday, May 29th. The stock was sold at an average price of $101.01, for a total transaction of $505,050.00. Following the completion of the transaction, the director now directly owns 6,249 shares of the company’s stock, valued at approximately $631,211.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jason A. Napolitano sold 5,502 shares of the business’s stock in a transaction on Thursday, May 31st. The stock was sold at an average price of $106.08, for a total value of $583,652.16. The disclosure for this sale can be found here. Insiders sold a total of 27,402 shares of company stock worth $2,884,523 in the last quarter. Company insiders own 14.70% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fred Alger Management Inc. grew its stake in Heska by 157.4% during the 2nd quarter. Fred Alger Management Inc. now owns 277,687 shares of the medical research company’s stock worth $28,821,000 after purchasing an additional 169,804 shares in the last quarter. Pendal Group Ltd grew its stake in Heska by 14.0% during the 2nd quarter. Pendal Group Ltd now owns 18,255 shares of the medical research company’s stock worth $1,895,000 after purchasing an additional 2,235 shares in the last quarter. Summit Creek Advisors LLC grew its stake in Heska by 14.2% during the 2nd quarter. Summit Creek Advisors LLC now owns 71,868 shares of the medical research company’s stock worth $7,459,000 after purchasing an additional 8,915 shares in the last quarter. Raymond James Trust N.A. acquired a new position in Heska during the 2nd quarter worth $240,000. Finally, Curbstone Financial Management Corp grew its stake in Heska by 11.8% during the 2nd quarter. Curbstone Financial Management Corp now owns 5,700 shares of the medical research company’s stock worth $592,000 after purchasing an additional 600 shares in the last quarter. 89.12% of the stock is owned by hedge funds and other institutional investors.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

See Also: Understanding Price to Earnings Ratio (PE)

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply